RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Incyte Corp. New release: Baricitinib demonstrates superiority to adalimumab in improving signs and symptoms of rheumatoid arthritis in pivotal phase 3 study. 2015 Oct 14.
S. National Institutes of Health. A study in moderate to severe rheumatoid srthritis (RA-BEAM). ClinicalTrials.gov. 2015 May.
Barber J. Eli Lilly, Incyte’s baricitinib hits main goal of Phase III rheumatoid arthritis study. FirstWord Pharma. 2014 Dec 9.
Eli Lilly and Comp., Incyte Corp. New release: Baricitinib superior to methotrexate in reducing signs and symptoms in pivotal phase 3 study in patients with rheumatoid arthritis. 2015 Sep 29.
U.S. Food and Drug Administration. Safety alerts for human medical products: Kayexalate (sodium polystyrene sulfonate): Drug safety communication—FDA requires drug interaction studies. 2015 Oct 22.

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Related Articles